JP2010509229A5 - - Google Patents

Download PDF

Info

Publication number
JP2010509229A5
JP2010509229A5 JP2009535417A JP2009535417A JP2010509229A5 JP 2010509229 A5 JP2010509229 A5 JP 2010509229A5 JP 2009535417 A JP2009535417 A JP 2009535417A JP 2009535417 A JP2009535417 A JP 2009535417A JP 2010509229 A5 JP2010509229 A5 JP 2010509229A5
Authority
JP
Japan
Prior art keywords
composition
catheter
tenecteplase
bfr
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009535417A
Other languages
English (en)
Japanese (ja)
Other versions
JP5871449B2 (ja
JP2010509229A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/082933 external-priority patent/WO2008070353A2/en
Publication of JP2010509229A publication Critical patent/JP2010509229A/ja
Publication of JP2010509229A5 publication Critical patent/JP2010509229A5/ja
Application granted granted Critical
Publication of JP5871449B2 publication Critical patent/JP5871449B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009535417A 2006-11-07 2007-10-30 組織プラスミノゲン活性化因子バリアントの使用 Active JP5871449B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86475806P 2006-11-07 2006-11-07
US60/864,758 2006-11-07
US98348907P 2007-10-29 2007-10-29
US60/983,489 2007-10-29
PCT/US2007/082933 WO2008070353A2 (en) 2006-11-07 2007-10-30 Tissue plasminogen activator variant uses

Publications (3)

Publication Number Publication Date
JP2010509229A JP2010509229A (ja) 2010-03-25
JP2010509229A5 true JP2010509229A5 (enExample) 2011-12-15
JP5871449B2 JP5871449B2 (ja) 2016-03-01

Family

ID=39362326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009535417A Active JP5871449B2 (ja) 2006-11-07 2007-10-30 組織プラスミノゲン活性化因子バリアントの使用

Country Status (10)

Country Link
US (1) US8916148B2 (enExample)
EP (1) EP2086571A2 (enExample)
JP (1) JP5871449B2 (enExample)
AR (1) AR063603A1 (enExample)
CA (1) CA2668347C (enExample)
CL (1) CL2007003211A1 (enExample)
PE (2) PE20120639A1 (enExample)
TW (1) TW200826981A (enExample)
UY (1) UY30693A1 (enExample)
WO (1) WO2008070353A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL371760A1 (en) 2001-11-26 2005-06-27 Genentech, Inc. Catheter composition and uses thereof
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
CA2668347C (en) 2006-11-07 2017-06-20 Genentech, Inc. Tissue plasminogen activator variant uses
MY171723A (en) 2010-12-23 2019-10-24 Gennova Biopharmaceuticals Ltd Pharmaceutical compositions of tenecteplase
GB201415062D0 (en) * 2014-08-26 2014-10-08 Aplagon Oy Therapeutic
MX383595B (es) * 2014-10-21 2025-03-14 Gennova Biopharmaceuticals Ltd Proceso novedoso de purificacion para el aislamiento y produccion comercial de tnk-tpa recombinante (tenecteplasa)

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI831484A7 (fi) 1982-05-05 1983-11-06 Genentech Inc Ihmiskudoksen plasminogeenien aktivaattori.
US5000185A (en) 1986-02-28 1991-03-19 Cardiovascular Imaging Systems, Inc. Method for intravascular two-dimensional ultrasonography and recanalization
US5019096A (en) 1988-02-11 1991-05-28 Trustees Of Columbia University In The City Of New York Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
US5270198A (en) 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
GB8820945D0 (en) 1988-09-07 1988-10-05 Smith & Nephew Medical articles
NZ230808A (en) 1988-10-24 1993-04-28 Squibb & Sons Inc Pharmaceutical compositions and combinations containing an angiotensin-converting enzyme inhibitor and a thrombolytic agent
AU7998091A (en) 1990-05-17 1991-12-10 Harbor Medical Devices, Inc. Medical device polymer
US5399158A (en) 1990-05-31 1995-03-21 The United States Of America As Represented By The Secretary Of The Army Method of lysing thrombi
US5363754A (en) 1991-09-03 1994-11-15 Grainco Queensland Co-Operative Association Limited Apparatus for preparing animal feedstuff from cotton seed
EP0786257B1 (en) 1992-06-03 2003-07-30 Genentech, Inc. Tissue plasminogen activator glycosylation variants with improved therapeutic properties
US5362754A (en) 1992-11-12 1994-11-08 Univ. Of Tx Md Anderson Cancer Center M-EDTA pharmaceutical preparations and uses thereof
US5688516A (en) 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
DE69426604T2 (de) 1993-11-24 2001-05-10 Dupont Pharmaceuticals Co., Wilmington Isoxazoline und isoxazole derivate als fibrinogen rezeptor antagonisten
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5885967A (en) 1994-03-04 1999-03-23 Eli Lilly And Company Antithrombotic agents
US5509896A (en) 1994-09-09 1996-04-23 Coraje, Inc. Enhancement of thrombolysis with external ultrasound
US5556380A (en) 1995-04-05 1996-09-17 Duke University Method for removing fibrin sheaths from catheters
CA2178541C (en) 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
US5772640A (en) 1996-01-05 1998-06-30 The Trustees Of Columbia University Of The City Of New York Triclosan-containing medical devices
US5932299A (en) 1996-04-23 1999-08-03 Katoot; Mohammad W. Method for modifying the surface of an object
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5837688A (en) 1996-11-27 1998-11-17 Gelfand; Mathew I. Use of thrombolytic reagents for prevention of vascular disease
GB9626795D0 (en) 1996-12-23 1997-02-12 Geistlich Soehne Ag Combating infection in delivery systems
WO1998028326A1 (en) 1996-12-23 1998-07-02 Biochem Pharma Inc. Bicyclic thrombin inhibitors
US5981826A (en) 1997-05-05 1999-11-09 Georgia Tech Research Corporation Poly(vinyl alcohol) cryogel
JPH10328293A (ja) 1997-06-04 1998-12-15 Unitika Ltd 医療用具及びその製造方法
US6206914B1 (en) 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
US6166007A (en) 1998-07-02 2000-12-26 Sodemann; Klaus Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof
US6174537B1 (en) 1998-09-25 2001-01-16 Becton, Dickinson And Company Catheter flush solution and method for its use
AU3625500A (en) 1999-03-11 2000-09-28 Du Pont Pharmaceuticals Company Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders
BR0010381A (pt) 1999-03-11 2002-02-05 Du Pont Pharm Co Método de tratamento da trombose em um mamìfero, e uso de uma combinação de (i) um inibidor do fator xa, e (ii) um composto selecionado do grupo que consiste em aspirina, tpa, um antagonista gpiib/iiia, heparina de baixo peso molecular e heparina
CA2302720C (en) 1999-03-29 2009-07-14 Ed Geistlich Sohne Ag Fur Chemische Industrie Anticoagulant/sterilizing compositions and methods
US6187768B1 (en) 1999-06-01 2001-02-13 Becton, Dickinson And Company Kit for flushing medical devices and method of preparation
EP1060747A3 (en) 1999-06-16 2001-12-05 New York Blood Center, Inc. Fibrin(ogen) degradation and clot lysis by fibrinolytic metalloproteinase
US6592564B2 (en) 1999-07-23 2003-07-15 Vasca, Inc. Methods and kits for locking and disinfecting implanted catheters
US6350251B1 (en) 2000-01-18 2002-02-26 Biolink Corporation Biocidal locks
US20010031981A1 (en) 2000-03-31 2001-10-18 Evans Michael A. Method and device for locating guidewire and treating chronic total occlusions
EP1284780B1 (en) 2000-05-10 2008-05-07 Ash Access Technology, Inc. A catheter lock solution including a photo-oxidant
WO2002017714A2 (en) 2000-08-25 2002-03-07 Organ Recovery Systems, Inc. Methods of thrombolytic organ treatment and repair
US20050215978A1 (en) * 2001-05-25 2005-09-29 Ash Stephen R Method of enhancing catheter patency using a citrate salt catheter lock solution
PL371760A1 (en) 2001-11-26 2005-06-27 Genentech, Inc. Catheter composition and uses thereof
US20070014779A1 (en) 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
EP1442753B1 (en) * 2003-02-03 2007-02-21 Polaschegg, Hans-Dietrich, Dr.techn. Composition for the prevention of indwelling device related infection
US7696182B2 (en) * 2004-11-02 2010-04-13 Nd Partners, Llc Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
US7749529B2 (en) * 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
CA2668347C (en) 2006-11-07 2017-06-20 Genentech, Inc. Tissue plasminogen activator variant uses

Similar Documents

Publication Publication Date Title
JP2021193130A (ja) 抗菌組成物およびその使用
JP2010509229A5 (enExample)
JP2018135383A (ja) 肺高血圧症のための治療
Chhibber et al. Anesthesia care for adult live donor hepatectomy: our experiences with 100 cases
Richard III et al. A randomized, prospective evaluation of the Tesio, Ash split, and Opti-flow hemodialysis catheters
JP2019504012A5 (enExample)
Kundra et al. The effect of inhaled milrinone versus inhaled levosimendan in pulmonary hypertension patients undergoing mitral valve surgery—a pilot randomized double-blind study
Montagnac et al. Indwelling silicone femoral catheters: experience of three haemodialysis centres.
JP2020504154A5 (enExample)
De Caridi et al. Effectiveness of prostaglandin E1 in patients with mixed arterial and venous ulcers of the lower limbs
Walensi et al. Mesenteric ischemia-reperfusion injury: Clearly improved hemodynamics but only minor protection of the rat small intestine by (sub) therapeutic heparin sodium and enoxaparin doses
de Gregorio et al. Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease
US20090285909A1 (en) Lactate and Calcium Containing Pharmaceutical Composition and Uses Thereof
WO2008070353A3 (en) Tissue plasminogen activator variant uses
CN104000809B (zh) 一种防治冠心病心绞痛的药物组合物及其应用
Lorente et al. Thrombosed internal hemodialysis access fistula: success of systemic fibrinolytic treatment
WO2006016351A3 (en) Drug delivery in the coronary sinus
Krowka Hepatopulmonary syndrome and portopulmonary hypertension
Alsaghir et al. Iloprost in pulmonary hypertension due to sub-massive pulmonary embolism: report of two cases
Gunatillake et al. Hemodialysis access infections, epidemiology, pathogenesis and prevention
Sombolos et al. Experience with the use of uncuffed double-lumen silicone hemodialysis catheters
JP2015526493A (ja) 冠動脈バイパス移植術を受けることが予定されている患者の非ｓｔ上昇型急性冠症候群の治療において使用するためのオタミキサバン
Zanwar et al. Comparison of epsilon aminocaproic acid and tranexamic acid to control postoperative bleeding in patients undergoing mitral valve replacement surgery-A randomised double blind trial
RU2008112667A (ru) Способы проведения чрескожного коронарного вмешательства
RU2019142647A (ru) Способ профилактики тромбоза системно-легочного шунта